- Home
- OPHC vs ACRV Comparison
OPHC vs ACRV Comparison
Compare OPHC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- ACRV
- Stock Information
- Founded
- OPHC 2000
- ACRV 2018
- Country
- OPHC United States
- ACRV United States
- Employees
- OPHC N/A
- ACRV N/A
- Industry
- OPHC Major Banks
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- OPHC Finance
- ACRV Health Care
- Exchange
- OPHC Nasdaq
- ACRV Nasdaq
- Market Cap
- OPHC 48.3M
- ACRV 47.8M
- IPO Year
- OPHC N/A
- ACRV 2022
- Fundamental
- Price
- OPHC $4.08
- ACRV $1.94
- Analyst Decision
- OPHC
- ACRV Buy
- Analyst Count
- OPHC 0
- ACRV 6
- Target Price
- OPHC N/A
- ACRV $17.75
- AVG Volume (30 Days)
- OPHC 34.7K
- ACRV 420.7K
- Earning Date
- OPHC 11-06-2025
- ACRV 11-07-2025
- Dividend Yield
- OPHC N/A
- ACRV N/A
- EPS Growth
- OPHC 6.01
- ACRV N/A
- EPS
- OPHC 1.28
- ACRV N/A
- Revenue
- OPHC $41,269,000.00
- ACRV N/A
- Revenue This Year
- OPHC N/A
- ACRV N/A
- Revenue Next Year
- OPHC N/A
- ACRV $805.34
- P/E Ratio
- OPHC $3.20
- ACRV N/A
- Revenue Growth
- OPHC 36.79
- ACRV N/A
- 52 Week Low
- OPHC $3.53
- ACRV $1.05
- 52 Week High
- OPHC $5.90
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- OPHC 49.74
- ACRV 54.47
- Support Level
- OPHC $3.94
- ACRV $1.92
- Resistance Level
- OPHC $4.02
- ACRV $2.18
- Average True Range (ATR)
- OPHC 0.08
- ACRV 0.15
- MACD
- OPHC 0.02
- ACRV -0.01
- Stochastic Oscillator
- OPHC 70.83
- ACRV 52.04
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.